Procaps Group S.A., established in Luxembourg in 1977, functions as a global pharmaceutical enterprise dedicated to the creation, production, and distribution of a broad spectrum of pharmaceutical solutions. The company manufactures and markets branded prescription medications addressing diverse therapeutic needs, including women's health, pain management, dermatological conditions, digestive disorders, growth and development, cardiovascular care, vision health, central nervous system ailments, and respiratory issues. In addition to prescription drugs, Procaps supplies a suite of products for hospital use, encompassing antibiotics, anticoagulants, personal protective equipment, immunosuppressants, oncology treatments, and analgesics. Its consumer healthcare division offers an extensive portfolio of over-the-counter (OTC) products across approximately eight primary therapeutic areas such as gastrointestinal health, skincare, cough and cold remedies, pain relievers, urological support, and a variety of vitamins, minerals, and dietary supplements. These offerings cover specific categories like anti-infectives, cardiovascular health, hormonal treatments, metabolic and endocrine support, nervous system medications, ophthalmic solutions, osteoarticular products, and more. Complementing its drug offerings, Procaps provides various diabetes management solutions, including blood glucose meters, telemonitoring devices, oral anti-diabetic medications, cosmeceuticals, and insulin delivery systems. The company also extends its expertise to third-party pharmaceutical companies through contract drug development and manufacturing services, with a particular specialization in soft gelatin capsule technologies.
